参考文献/References:
[1] Kharitonenkov A,Shiyanova TL,Koester A,et al.FGF-21 as a novel metabolic regulator[J].J Clin Investig,2005,115(6):1627-1635.DOI:10.1172/JCI23606.
[2] Keinicke H,Sun G,Mentzel CMJ,et al.FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation[J].Endocr Connect,2020,9(8):755-768.DOI:10.1530/EC-20-0152.
[3] Talukdar S,Zhou Y,Li D,et al.A long-acting FGF21 molecule,PF-05231023,decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects[J].Cell Metab,2016,23(3):427-440.DOI:10.1016/j.cmet.2016.02.001.
[4] Geng L,Lam KSL,Xu A.The therapeutic potential of FGF21 in metabolic diseases:from bench to clinic[J].Nat Rev Endocrinol,2020,16(11):654-667.DOI:10.1038/s41574-020-0386-0.
[5] Gilroy CA,Capozzi ME,Varanko AK,et al.Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia[J].Sci Adv,2020,6(35):eaaz9890.DOI:10.1126/sciadv.aaz9890.
[6] Nishimura T,Nakatake Y,Konishi M,et al.Identification of a novel FGF,FGF-21,preferentially expressed in the liver[J].Biochim Biophys Acta,2000,1492(1):203-206.DOI:10.1016/s0167-4781(00)00067-1.
[7] Lee S,Choi J,Mohanty J,et al.Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling[J].Nature,2018,553(7689):501-505.DOI:10.1038/nature25010.
[8] Geng L,Liao B,Jin L,et al.Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues[J].Cell Rep,2019,26(10):2738-2752.DOI:10.1016/j.celrep.2019.02.014.
[9] Cuevas-Ramos D,Aguilar-Salinas CA.Modulation of energy balance by fibroblast growth factor 21[J].Horm Mol Biol Clin Investig,2016,30(1):/j/hmbci.2017.30.issue-1/hmbci-2016-0023/hmbci-2016-0023.xml.DOI:10.1515/hmbci-2016-0023.
[10] Keuper M,Häring HU,Staiger H.Circulating FGF21 levels in human health and metabolic disease[J].Exp Clin Endocrinol Diabetes,2020,128(11):752-770.DOI:10.1055/a-0879-2968.
[11] Douris N,Stevanovic DM,Fisher FM,et al.Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice[J].Endocrinology,2015,156(7):2470-2481.DOI:10.1210/en.2014-2001.
[12] Schlein C,Talukdar S,Heine M,et al.FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues[J].Cell Metab,2016,23(3):441-453.DOI:10.1016/j.cmet.2016.01.006.
[13] Lu W,Li X,Luo Y.FGF21 in obesity and cancer:new insights[J].Cancer Lett,2021,499:5-13.DOI:10.1016/j.canlet.2020.11.026.
[14] Tillman EJ,Rolph T.FGF21:an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases[J].Front Endocrinol(Lausanne),2020,11:601290.DOI:10.3389/fendo.2020.601290.
[15] Epperlein S,Gebhardt C,Rohde K,et al.The effect of FGF21 and its genetic variants on food and drug cravings,adipokines and metabolic traits[J].Biomedicines,2021,9(4):345.DOI:10.3390/biomedicines9040345.
[16] Yan J,Nie Y,Cao J,et al.The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases[J].Front Cardiovasc Med,2021,8:655575.DOI:10.3389/fcvm.2021.655575.
[17] Charles ED,Neuschwander-Tetri BA,Pablo FJ,et al.Pegbelfermin(BMS-986036),PEGylated FGF21,in patients with obesity and type 2 diabetes:results from a randomized phase 2 study[J].Obesity(Silver Spring),2019,27(1):41-49.DOI:10.1002/oby.22344.
[18] Sanyal A,Charles ED,Neuschwander-Tetri BA,et al.Pegbelfermin(BMS-986036),a PEGylated fibroblast growth factor 21 analogue,in patients with non-alcoholic steatohepatitis:a randomised,double-blind,placebo-controlled,phase 2a trial[J].Lancet,2019,392(10165):2705-2717.DOI:10.1016/S0140-6736(18)31785-9.
[19] Harrison SA,Ruane PJ,Freilich BL,et al.Efruxifermin in non-alcoholic steatohepatitis:a randomized,double-blind,placebo-controlled,phase 2a trial[J].Nat Med,2021,27(7):1262-1271.DOI:10.1038/s41591-021-01425-3.
[20] Pan Q,Lin S,Li Y,et al.A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis[J].EBioMedicine,2021,63:103202.DOI:10.1016/j.ebiom.2020.103202.
[21] Zhu L,Zhao H,Liu J,et al.Dynamic folding modulation generates FGF21 variant against diabetes[J].EMBO Rep,2021,22(1):e51352.DOI:10.15252/embr.202051352.
[22] Depaoli A,Phung V,Bashir MR,et al.140-LB:NGM313,a novel activator of b-klotho/FGFR1c,improves insulin resistance and reduces hepatic fat in obese,nondiabetic subjects[J].Diabetes,2019,68:140.DOI:10.2337/db19-140-LB.
[23] Guo C,Zhao L,Li Y,et al.Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus[J].J Cell Physiol,2021,236(1):55-67.DOI:10.1002/jcp.29879.
[24] Tan H,Yue T,Chen Z,et al.Targeting FGF21 in cardiovascular and metabolic diseases:from mechanism to medicine[J].Int J Biol Sci,2023,19(1):66-88.DOI:10.7150/ijbs.73936.
[25] Kim AM,Somayaji VR,Dong JQ,et al.Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids,bone turnover markers,blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates[J].Diabetes Obes Metab,2017,19(12):1762-1772.DOI:10.1111/dom.13023.
相似文献/References:
[1]冯静,魏亚聪,宋光耀.成纤维细胞生长因子21与胰岛素抵抗[J].国际内分泌代谢杂志,2015,(04):268.[doi:10.3760/cma.j.issn.1673-4157.2015.04.015]
Feng Jing*,Wei Yacong,Song Guangyao..Fibroblast growth factor 21 and insulin resistance[J].International Journal of Endocrinology and Metabolism,2015,(02):268.[doi:10.3760/cma.j.issn.1673-4157.2015.04.015]
[2]柯孟婷,孙家忠,李扬.3,5-二碘-L-甲状腺素对白色脂肪棕色化的作用[J].国际内分泌代谢杂志,2016,36(06):370.[doi:10.3760/cma.j.issn.1673-4157.2016.06.03]
Ke Mengting*,Sun Jiazhong,Li Yang..Effects of 3,5-diiodo-L-thyronine on browning of white adipose tissue[J].International Journal of Endocrinology and Metabolism,2016,36(02):370.[doi:10.3760/cma.j.issn.1673-4157.2016.06.03]
[3]高胜利,郭菲菲,徐珞,等.Nesfatin-1与肥胖的关系[J].国际内分泌代谢杂志,2016,36(06):384.[doi:10.3760/cma.j.issn.1673-4157.2016.06.06]
Gao Shengli,Guo Feifei,Xu Luo,et al.Relationship between nesfatin-1 and obesity[J].International Journal of Endocrinology and Metabolism,2016,36(02):384.[doi:10.3760/cma.j.issn.1673-4157.2016.06.06]
[4]杨曦,刘玉洁,马慧娟.生长分化因子15与肥胖及糖尿病[J].国际内分泌代谢杂志,2016,36(06):388.[doi:10.3760/cma.j.issn.1673-4157.2016.06.07]
Yang Xi*,Liu Yujie,Ma Huijuan..Growth differentiation factor-15 and obesity, diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(02):388.[doi:10.3760/cma.j.issn.1673-4157.2016.06.07]
[5]刘玉洁,杨曦,马慧娟.MC4R在肥胖及糖代谢中的作用[J].国际内分泌代谢杂志,2016,36(06):391.[doi:10.3760/cma.j.issn.1673-4157.2016.06.08]
Liu Yujie*,YangXi,Ma Huijuan..Role of MC4R in obesity and glucose metabolism[J].International Journal of Endocrinology and Metabolism,2016,36(02):391.[doi:10.3760/cma.j.issn.1673-4157.2016.06.08]
[6]姚旻,赵爱源,李红涛,等.人体肥胖指数在评价2型糖尿病患者
肥胖中的应用价值[J].国际内分泌代谢杂志,2017,37(01):1.[doi:10.3760/cma.j.issn.1673-4157.2017.01.01]
Yao Min*,Zhao Aiyuan,Li Hongtao,et al.Body adiposity index and its value in obesity evaluation in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2017,37(02):1.[doi:10.3760/cma.j.issn.1673-4157.2017.01.01]
[7]严克敏,朱惠娟,龚凤英.雷公藤红素:一种潜在的治疗肥胖症的新药物[J].国际内分泌代谢杂志,2017,37(01):32.[doi:10.3760/cma.j.issn.1673-4157.2017.01.09]
Yan Kemin,Zhu Huijuan,Gong Fengying..Celastrol:a potential and novel drug for obesity[J].International Journal of Endocrinology and Metabolism,2017,37(02):32.[doi:10.3760/cma.j.issn.1673-4157.2017.01.09]
[8]张群慧,陈明卫.miRNA与肥胖[J].国际内分泌代谢杂志,2017,37(01):35.[doi:10.3760/cma.j.issn.1673-4157.2017.01.10]
Zhang Qunhui,Chen Mingwei..microRNA and obesity[J].International Journal of Endocrinology and Metabolism,2017,37(02):35.[doi:10.3760/cma.j.issn.1673-4157.2017.01.10]
[9]梁绮君,胡晨鸣,黄容,等.山楂消脂胶囊对肥胖症患者炎性状态
及脂多糖水平的影响[J].国际内分泌代谢杂志,2017,37(04):236.
Liang Qijun,Hu Chenming,Huang Rong,et al.Effects of Shanzha xiaozhi capsule on inflammation and lipopolysaccharide level in obese patients[J].International Journal of Endocrinology and Metabolism,2017,37(02):236.
[10]马骥,都健.代谢手术影响骨代谢的机制研究[J].国际内分泌代谢杂志,2017,37(05):312.
Ma Ji,Du Jian..Mechanism study of effects of metabolic surgery on bone metabolism[J].International Journal of Endocrinology and Metabolism,2017,37(02):312.